SCHEMBL24008156

SCHEMBL24008156

CC1(C)CC(Cn2nc(C3CC3)cc(NC(=O)C(C)(C)C)c2=O)CO1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMIGD3 P0DMS9 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ GRM4 Q14833 4/20 0.33
▸ KCNJ6 P48051 3/20 0.32
▸ KCNJ5 P48544 3/20 0.32
▸ KCNJ3 P48549 3/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ F2 P00734 2/20 0.32
▸ HTR1A P08908 2/20 0.32
▸ DRD2 P14416 2/20 0.32
▸ DRD4 P21917 2/20 0.32
▸ KCNH2 Q12809 1/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ OPRK1 P41145 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MITF O75030 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24815180 0.86 KDM4E (0.35) GRM4GAAKCNH2KDM4EMITF
SCHEMBL24815095 0.81 PDE4B (0.30) —
SCHEMBL25745857 0.80 OPRM1 (0.32) KCNJ6KCNJ5KCNJ3OPRM1ALDH1A1
SCHEMBL24008157 0.79 GRM4 (0.33) GRM4
SCHEMBL24008158 0.78 — —
SCHEMBL25748101 0.77 PDE4B (0.30) —
SCHEMBL25746180 0.74 — —
SCHEMBL24007637 0.74 ADORA1 (0.46) TMIGD3ADORA1CYP3A4GAACYP2C19
SCHEMBL24567211 0.72 TMIGD3 (0.39) TMIGD3ADORA1CYP3A4GAACYP2C19
SCHEMBL24567226 0.72 TMIGD3 (0.39) TMIGD3ADORA1CYP3A4GAACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 — — US disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B TMIGD3 3941/4885ADORA1 4060/4885GRM4 3983/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B TMIGD3 3941/4885ADORA1 4060/4885GRM4 3983/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B TMIGD3 3941/4885ADORA1 4060/4885GRM4 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback